Pancreatic and Hepatic Oncology Research
Moving in EMBO Journal, Nature Medicine, Nature Reviews Drug Discovery, New England Journal of Medicine.
- Moved this week
- 4
Rebuilt
Moved this week
Over 59% of pancreatic cancer patients treated with daraxonrasib develop resistance through RAS pathway alterations, including KRAS amplification and RTK upregulation.
- Open access
- 5 cites
CDK8 drives immune evasion and resistance in PDAC by remodeling the tumor microenvironment during KRAS G12D inhibition, with 50% of cases showing resistance.
- Open access
- 3 cites
Daraxonrasib significantly improves overall survival and progression-free survival in previously treated metastatic pancreatic ductal adenocarcinoma, with median overall survival of 13.2 months versus 6.6 months for chemotherapy.
- 97 cites
Latest in Pancreatic and Hepatic Oncology Research
Newest first · last 60 days
Asynchronous evolution of epithelial and stromal components distinguishes pancreatic cancer from precursor lesions, with stromal reprogramming being a key differentiator.
- Open access
Exercise reduces stromal fibroblasts and inflammatory signals in pancreatic cancer, with a 50% decrease in αSMA+ cells linked to microbial metabolites.
- Open access
Implementing EHR-based risk models with imaging and blood tests detects pancreatic cancer early in 8.2% of high-risk adults aged 50-84.
- Open access
Targeting RAS mutations offers promising strategies for intercepting pancreatic cancer at its precancerous stage.
A blood-based microRNA assay combined with carbohydrate antigen 19-9 detects early-stage pancreatic ductal adenocarcinoma with 86.8% sensitivity in a large international study.
Reg-EXTL3 axis promotes nerve-cancer interactions in pancreatic ductal adenocarcinoma, with silencing reducing tumor progression and pain in mice.
- 3 cites
Targeting multiple overlooked factors, the Heracles Protocol offers a comprehensive approach to make pancreatic ductal adenocarcinoma more treatable.
Serpine1 and Serpinb2 drive immune evasion in pancreatic ductal carcinoma by shaping immunosuppressive microenvironments in spatially restricted niches.
- Open access
Combining radiotherapy and immunotherapy offers a promising approach to improve survival in localized pancreatic ductal adenocarcinoma, despite current challenges.
Distinct epithelial and fibroblast features in pancreatitis and PDAC are revealed through multi-stromal organoid co-cultures, highlighting disease-specific heterogeneity.
- Open access
HRS-4642 combined with chemotherapy achieves a 63.3% objective response rate in advanced KRAS(G12D)-mutant pancreatic cancer, showing promising antitumor activity.
KRAS mutations in pancreatic ductal adenocarcinoma drive cytokine and metabolic crosstalk that causes immune exclusion, with key pathways involving STAT3, NF-κB, HIF-1α, and MYC.
- Open access
Follow this area in the app
Browse JClub
Journals this month
- bioRxiv5569
- medRxiv1746
- Environ Res485
- PNAS463
- Sci Adv439
- JAMA255
- Cell Rep210
- BMJ205
- Nat Commun177
- Environ Pollution170
- Lancet149
- Science138
- NEJM119
- Applied & Environ Microbio116
- Curr Biol116
- J Exp Bot115
- mBio109
- Nature104
Moving areas, week to 3 Oct 2026
- Single-cell and spatial transcriptomics10
- Artificial Intelligence in Healthcare and Education8
- CAR-T cell therapy research7
- Neuroinflammation and Neurodegeneration Mechanisms6
- Lung Cancer Treatments and Mutations5
- Diabetes Treatment and Management4
- Pancreatic and Hepatic Oncology Research4
- Photosynthetic Processes and Mechanisms4
- Genomics and Chromatin Dynamics4
- Gut microbiota and health4